Encyclopedia of Signaling Molecules

Living Edition
| Editors: Sangdun Choi

Vitronectin

  • Klaus T. Preissner
Living reference work entry
DOI: https://doi.org/10.1007/978-1-4614-6438-9_101907-1

Synonyms

Historical Background

VN was first described as a “serum spreading factor” to promote the attachment and spreading of cells to various surfaces, and it is this property of plasma/serum that enables mammalian cells to adhere to culture dishes and propagate (Leavesley et al. 2013). Unrelated investigations in cellular movement and epiboly as well as in innate immunity lead to the term “epibolin” or the discovery of VN as the complement inhibitor “S-protein,” respectively, whereby the identity of both factors was uncovered 30 years ago by the author.

VN Gene and Expression of the VN Protein

Gene Structure

The human VN gene (about 3.5 kb) is localized on chromosome 17 (centromeric region 17q11); the murine VN gene is found on chromosome 10. Both VN genes consist of eight exons and seven introns, resulting in 1.7 kb transcripts without indication for alternative splicing (Jenne and Stanley 1987...

Keywords

Neisseria Gonorrhoeae Met381Thr Polymorphism Focal Adhesion Site Pericellular Proteolysis Macromolecular Ligand 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

References

  1. Andreasen PA, Kjøller L, Christensen L, Duffy MJ. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer. 1997;72:1–22.CrossRefPubMedGoogle Scholar
  2. Bergmann S, Lang A, Rohde M, Agarwal V, Rennemeier C, Grashoff C, Preissner KT, Hammerschmidt S. Integrin-linked kinase is required for vitronectin-mediated internalization of Streptococcus pneumoniae by host cells. J Cell Sci. 2009;122:256–67. doi: 10.1242/jcs.035600.CrossRefPubMedGoogle Scholar
  3. Chapman HA. Plasminogen activators, integrins, and the coordinated regulation of cell adhesion and migration. Curr Opin Cell Biol. 1997;9:714–24.CrossRefPubMedGoogle Scholar
  4. Declerck PJ, De Mol M, Alessi MC, Baudner S, Pâques EP, Preissner KT, Müller-Berghaus G, Collen D. Purification and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma. Identification as a multimeric form of S protein (vitronectin). J Biol Chem. 1988;263:15454–61.PubMedGoogle Scholar
  5. Eitzman DT, Westrick RJ, Nabel EG, Ginsburg D. Plasminogen activator inhibitor-1 and vitronectin promote vascular thrombosis in mice. Blood. 2000;95:577–80.PubMedGoogle Scholar
  6. Hallström T, Singh B, Kraiczy P, Hammerschmidt S, Skerka C, Zipfel PF, Riesbeck K. Conserved patterns of microbial immune escape: Pathogenic microbes of diverse origin target the human terminal complement inhibitor vitronectin via a single common motif. PLoS One. 2016;11:e0147709. doi: 10.1371/journal.pone.0147709.CrossRefPubMedPubMedCentralGoogle Scholar
  7. Harbeck N, Kates RE, Schmitt M, Gauger K, Kiechle M, Janicke F, Thomassen C, Look MP, Foekens JA. Urokinase-type plasminogen activator and its inhibitor type 1 predict disease outcome and therapy response in primary breast cancer. Clin Breast Cancer. 2004;5:348–52.CrossRefPubMedGoogle Scholar
  8. Jenne D, Stanley KK. Nucleotide sequence and organization of the human S-protein gene: repeating peptide motifs in the “pexin” family and a model for their evolution. Biochemistry. 1987;26:6735–42.CrossRefPubMedGoogle Scholar
  9. Kenny HA, Kaur S, Coussens LM, Lengyel E. The initial steps of ovarian cancer cell metastasis are mediated by MMP-2 cleavage of vitronectin and fibronectin. J Clin Invest. 2008;118:1367–79. doi: 10.1172/JCI33775.CrossRefPubMedPubMedCentralGoogle Scholar
  10. Leavesley DI, Kashyap AS, Croll T, Sivaramakrishnan M, Shokoohmand A, Hollier BG, Upton Z. Vitronectin: master controller or micromanager? IUBMB Life. 2013;65:807–18. doi: 10.1002/iub.1203.PubMedGoogle Scholar
  11. Lim BL, Reid KB, Ghebrehiwet B, Peerschke EI, Leigh LA, Preissner KT. The binding protein for globular heads of complement C1q, gC1qR. Functional expression and characterization as a novel vitronectin binding factor. J Biol Chem. 1996;271:26739–44.CrossRefPubMedGoogle Scholar
  12. Podack ER, Preissner KT, Müller-Eberhard HJ. Inhibition of C9 polymerization within the SC5b-9 complex of complement by S-protein. Acta Pathol Microbiol Immunol Scand Suppl. 1984;284:89–96.PubMedGoogle Scholar
  13. Preissner KT, Wassmuth R, Müller-Berghaus G. Physicochemical characterization of human S-protein and its function in the blood coagulation system. Biochem J. 1985;231:349–55.Google Scholar
  14. Preissner KT. Structure and biological role of vitronectin. Annu Rev Cell Biol. 1991;7:275–310.CrossRefPubMedGoogle Scholar
  15. Preissner KT, Chhatwal GS. Extracellular matrix and host cell surfaces: potential sites of pathogen interaction. In: Cossart P, Boquet P, Normark S, Rappuoli R, editors. Cellular microbiology. 2nd ed. Washington, DC: ASM Press; 2005. p. 88–105. Google Scholar
  16. Preissner KT, Reuning U. Vitronectin in vascular context: facets of a multitalented matricellular protein. Semin Thromb Hemost. 2011;37:408–24. doi: 10.1055/s-0031-1276590.CrossRefPubMedGoogle Scholar
  17. Schmidt CQ, Lambris JD, Ricklin D. Protection of host cells by complement regulators. Immunol Rev. 2016;274:152–71. doi: 10.1111/imr.12475.CrossRefPubMedGoogle Scholar
  18. Seiffert D. Constitutive and regulated expression of vitronectin. Histol Histopathol. 1997;12:787–97.PubMedGoogle Scholar
  19. Seiffert D, Keeton M, Eguchi Y, Sawdey M, Loskutoff DJ. Detection of vitronectin mRNA in tissues and cells of the mouse. Proc Natl Acad Sci USA. 1991;88:9402–6.CrossRefPubMedPubMedCentralGoogle Scholar
  20. Seiffert D, Loskutoff DJ. Evidence that type 1 plasminogen activator inhibitor binds to the somatomedin B domain of vitronectin. J Biol Chem. 1991;266:2824–30.PubMedGoogle Scholar
  21. Tomasini BR, Mosher DF. Vitronectin. Prog Hemost Thromb. 1991;10:269–305.PubMedGoogle Scholar
  22. Upton Z, Cuttle L, Noble A, Kempf M, Topping G, Malda J, Xie Y, Mill J, Harkin DG, Kravchuk O, Leavesley DI, Kimble RM. Vitronectin: growth factor complexes hold potential as a wound therapy approach. J Invest Dermatol. 2008;128:1535–44. doi: 10.1038/sj.jid.5701148.CrossRefPubMedGoogle Scholar
  23. Yi M, Sakai T, Fässler R, Ruoslahti E. Antiangiogenic proteins require plasma fibronectin or vitronectin for in vivo activity. Proc Natl Acad Sci USA. 2003;100:11435–8. doi: 10.1073/pnas.1635112100.CrossRefPubMedPubMedCentralGoogle Scholar
  24. Zheng X, Saunders TL, Camper SA, Samuelson LC, Ginsburg D. Vitronectin is not essential for normal mammalian development and fertility. Proc Natl Acad Sci USA. 1995;92:12426–30.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media LLC 2016

Authors and Affiliations

  1. 1.Department of BiochemistryMedical School, Justus-Liebig-UniversityGiessenGermany